Results 191 to 200 of about 183,644 (348)

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Structural and Computational Insights into the Angiotensin II Type 1 Receptor: Advances in Antagonist Design and Implications for Hypertension Therapy (2020-2024). [PDF]

Biomolecules
Chatzipieris FP, Petsas E, Lambrinidis G, Matsoukas JM, Mavromoustakos T.   +4 more
europepmc   +1 more source

Angiotensin II Type 1 Receptor Blocker Prevents Abdominal Aortic Aneurysm Progression in Osteoprotegerin-Deficient Mice via Upregulation of Angiotensin (1-7). [PDF]

J Am Heart Assoc, 2023
Karasaki K, Kokubo H, Bumdelger B, Kaji N, Sakai C, Ishida M, Yoshizumi M.   +6 more
europepmc   +1 more source

Mechanoactivation of the angiotensin II type 1 receptor induces β‐arrestin‐biased signaling through Gα_icoupling

, 2017
Jialu Wang, Kenji Hanada, Clarice Gareri, Howard A. Rockman   +3 more
openalex   +1 more source

Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation.

Journal of the American College of Cardiology, 2003
K. Kumagai, H. Nakashima, H. Urata, N. Gondo, Kikuo Arakawa, K. Saku   +5 more
semanticscholar   +1 more source

Renin; angiotensin II type 1 (AT1) receptor [PDF]

Science-Business eXchange, 2008
openaire   +1 more source

Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator

ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh, Katharina Koepsel, Julia W. Erath, Thomas Kuntz, Norbert Klein, Boldizsar Kovacs, Firat Duru, Ardan M. Saguner, Christian Blockhaus, Dong‐In Shin, Fabienne Kreimer, Michael Gotzmann, Hendrik Lapp, Thomas Beiert, Assem Aweimer, Andreas Mügge, Christel Weiß, Ibrahim El‐Battrawy, Ibrahim Akin   +18 more
wiley   +1 more source

Autoantibodies directed against the angiotensin II type 1 receptor and the endothelin-1 type A receptor in patients with systemic sclerosis. [PDF]

RMD Open
van der Wouden KE, Ahmed S, van Oostveen WM, Hoekstra EM, Liem SIE, Huizinga TWJ, Toes REM, Voskuyl AE, Riemekasten G, Fehres CM, Vonk M, de Vries-Bouwstra JK.   +11 more
europepmc   +1 more source

Type-1 Angiotensin II Receptor-Associated Protein [PDF]

, 2020
openaire   +1 more source

Connecting the dots: A narrative review of the relationship between heart failure and cognitive impairment

ESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.
Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi, Maria Giulia Bellicini, Marianna Adamo, Andrea Pilotto, Marco Metra, Alessandro Padovani, Riccardo Proietti   +6 more
wiley   +1 more source